Replimune Group Inc (REPL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Replimune Group Inc (REPL) Financials: Revenue, Profit and Cash Flow
Replimune Group reported revenue of $0 for the fiscal year ended Mar 31, 2026. That year, net income was -$313.94M, operating cash flow was -$280.34M and free cash flow was -$284.57M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$57.12M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Mar 2026, with an operating loss of $319.92M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $0 | N/A | N/A | N/A | N/A |
| Mar 2025 | $0 | N/A | N/A | N/A | N/A |
| Mar 2024 | $0 | N/A | N/A | N/A | N/A |
| Mar 2023 | $0 | N/A | N/A | N/A | N/A |
| Mar 2022 | $0 | N/A | N/A | N/A | N/A |
| Mar 2021 | $0 | N/A | N/A | N/A | N/A |
| Mar 2020 | $0 | N/A | N/A | N/A | N/A |
| Mar 2019 | $0 | N/A | N/A | N/A | N/A |
| Mar 2018 | $0 | N/A | N/A | N/A | N/A |
| Mar 2017 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Mar 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122.00K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$122.00K |
| Research and development | $221.18M | $189.45M | $173.04M | $126.53M | $79.55M | $56.75M | $38.76M | $22.17M | $13.52M | $6.94M |
| Operating income | -$319.92M | -$261.63M | -$234.77M | -$177.08M | -$118.31M | -$79.95M | -$56.20M | -$30.95M | -$19.23M | -$9.65M |
| Net income | -$313.94M | -$247.30M | -$215.79M | -$174.28M | -$118.04M | -$80.87M | -$55.71M | -$30.83M | -$19.70M | -$7.70M |
| EBITDA | -$316.04M | N/A | N/A | N/A | -$111.84M | -$74.73M | N/A | N/A | N/A | -$8.08M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.47M | $0 | $0 | $0 | $4.04M | $0 |
| Gross profit | $0 | $0 | N/A | $0 | $0 | $0 | -$848.00K | $0 | $0 | $0 | $3.39M | $0 |
| Operating income | -$56.28M | -$68.25M | -$73.34M | -$71.87M | -$84.29M | -$90.42M | -$79.33M | -$66.02M | -$58.92M | -$57.37M | -$58.75M | -$56.54M |
| Net income | -$57.12M | -$69.77M | -$73.22M | -$70.93M | -$83.10M | -$86.69M | -$74.13M | -$66.34M | -$53.05M | -$53.77M | -$55.08M | -$51.12M |
Balance Sheet
As of Mar 2026, cash and equivalents exceeded total debt of $87.35M by $121.67M.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $332.39M | $551.33M | $487.72M | $646.59M | $461.19M | $543.10M | $234.10M | $154.33M | $65.15M | $22.82M |
| Current assets | $279.12M | $495.88M | $433.67M | $592.60M | $403.98M | $483.75M | $174.25M | $140.98M | $64.70M | $22.40M |
| Cash and equivalents | $209.02M | $111.12M | $74.46M | $146.59M | $105.95M | $182.52M | $59.50M | $25.70M | $17.58M | $20.59M |
| Total liabilities | $166.23M | $135.49M | $113.21M | $91.30M | $49.96M | $44.37M | $50.38M | $16.47M | $6.86M | $34.33M |
| Short-term debt | $4.04M | $3.98M | $3.88M | $3.76M | $3.63M | $3.46M | $3.28M | N/A | N/A | N/A |
| Long-term debt | $83.31M | $46.38M | $44.81M | $28.65M | N/A | N/A | $9.80M | $0 | N/A | N/A |
| Shareholder equity | $166.16M | $415.84M | $374.51M | $555.29M | $411.23M | $498.73M | $183.72M | $137.86M | -$28.07M | -$11.52M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $373.94M | $252.45M | $332.39M | $333.59M | $389.45M | $469.51M | $551.33M | $603.63M | $498.20M | $534.97M | $487.72M | $532.93M |
| Total liabilities | $169.16M | $146.80M | $166.23M | $123.05M | $126.11M | $132.79M | $135.49M | $121.25M | $116.74M | $108.51M | $113.21M | $111.39M |
| Cash and equivalents | $307.83M | $185.36M | $209.02M | $122.95M | $102.30M | $97.37M | $111.12M | $172.25M | $113.49M | $151.66M | $74.46M | $97.67M |
| Shareholder equity | $204.78M | $105.64M | $166.16M | $210.54M | $263.34M | $336.71M | $415.84M | $482.37M | $381.46M | $426.45M | $374.51M | $421.54M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Mar 2026.
Annual
| Line item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$280.34M | -$192.25M | -$185.47M | -$128.05M | -$82.18M | -$61.39M | -$60.55M | -$25.38M | -$16.01M | -$7.08M |
| Capital expenditures | $4.22M | $6.69M | $5.66M | $2.27M | $2.34M | $2.39M | $6.54M | $2.60M | $136.00K | $238.00K |
| Free cash flow | -$284.57M | -$198.94M | -$191.13M | -$130.32M | -$84.52M | -$63.78M | -$67.09M | -$27.98M | -$16.15M | -$7.32M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $91.65M | $28.14M | N/A | N/A | N/A |
| Share repurchases | N/A | N/A | N/A | N/A | N/A | $100.00K | $355.00K | $2.16M | $0 | N/A |
| Investing cash flow | $310.84M | -$23.80M | $97.20M | -$142.50M | -$1.81M | -$188.78M | -$5.23M | -$65.94M | -$44.05M | -$238.00K |
| Financing cash flow | $66.29M | $252.40M | $16.28M | $311.30M | $6.60M | $372.46M | $100.17M | $101.39M | $54.75M | $15.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.70M | -$75.73M | -$56.16M | -$65.95M | -$81.21M | -$77.02M | -$53.73M | -$50.71M | -$38.64M | -$49.17M | -$46.17M | -$47.12M |
| Capital expenditures | $77.00K | $6.00K | $5.00K | $135.00K | $1.34M | $2.74M | $1.13M | $1.80M | $2.08M | $1.67M | $1.74M | $1.72M |
| Free cash flow | -$47.78M | -$75.73M | -$56.17M | -$66.09M | -$82.56M | -$79.76M | -$54.87M | -$52.51M | -$40.72M | -$50.84M | -$47.91M | -$48.84M |
Frequently Asked Questions About REPL
What is Replimune Group's annual revenue?
Replimune Group reported revenue of $0 for the fiscal year ended Mar 31, 2026.
Is Replimune Group profitable?
No. Replimune Group reported net income of -$313.94M for the fiscal year ended Mar 31, 2026.
How much free cash flow does REPL generate?
For the fiscal year ended Mar 31, 2026, operating cash flow of -$280.34M minus capital expenditures of $4.22M produced free cash flow of -$284.57M.
How much debt does Replimune Group have?
The balance sheet dated Mar 31, 2026 reported long-term debt of $83.31M, short-term debt of $4.04M and cash and equivalents of $209.02M.
REPL pages: Overview, Earnings, Forecast, Financials, Competitors